The global myotonic dystrophy drug market is anticipated to grow at a considerable CAGR of 7.6% during the forecast period (2024-2031). The market players in global myotonic dystrophy drug market are involved in strategic alliances like mergers & acquisitions, partnerships, business expansion, funding, and collaborations to contribute to the myotonic dystrophy makret. For instance, in April 2022, Expansion Therapeutics, received $55.3M in Series A financing for the development of therapies targeted at expanded repeat disorders, including myotonic dystrophy (DM1 and DM2). Similarly, in Dec 2021, AMO PHARMA announced their completion of two trial clinical sites in Australia and New Zealand for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02 to treat myotonic dystrophy.
Get Free Sample link @ https://www.omrglobal.com/request-sample/myotonic-dystrophy-drug-market
Moreover, the US FDA approvals for the myotonic dystrophy drug has created lucrative opportunities in the market and has opened path for market players for the further development of novel drugs. For instance, in October 2021, FDA has granted fast track designation to AOC 1001, an investigational treatment for myotonic dystrophy. On May 3, 2021, ICREA Researcher Professor and head of the Biosensors for Bioengineering group at IBEC developed a three-dimensional model for myotonic dystrophy using bioengineering technique and patient cells. In June 07, 2021, University of Virginia School of Medicine researchers have identified new insights and potential treatment approaches for muscle loss in myotonic dystrophy.
Full report of Myotonic Dystrophy Drug Market available @ https://www.omrglobal.com/industry-reports/myotonic-dystrophy-drug-market
Market Coverage
- Segment Covered-
o By Drug Type
o By Route of Administration
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape – ANI Pharmaceuticals, Inc., Lupin Ltd., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., and others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Myotonic Dystrophy Drug Market Report Segment
By Drug Type
- Sodium channel blockers
- NSAIDs
- Antidepressants
- Others
By Route of Administration
- Oral
- Intravenous
By Distribution channel
- Online pharmacies
- Offline pharmacies
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/myotonic-dystrophy-drug-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
